SKYE — Skye Bioscience, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1516551 ·
Last close
$0.82
Market Cap
$28.89M
52W High
$1.12
52W Low
$0.57
ADV30
204,847
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -12,674,366 | -12,509,361 | 19,416,736 | 8,149,015 | 10,404,932 |
| Dec 2025 | 0 | — | -14,895,544 | -14,441,963 | 28,313,633 | 5,882,498 | 8,289,458 |
| Sep 2025 | 0 | — | -13,264,534 | -12,754,660 | 41,324,289 | 18,441,079 | 8,488,104 |
| Jun 2025 | 0 | — | -18,243,925 | -17,624,872 | 52,160,911 | 23,838,244 | 8,484,202 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,062,529
Investing CF
$-19,500,285
Financing CF
$29,571
CapEx
$-1,574,695
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-186,874,486
Inventory
—
Receivables
$10,474
ST Investments
$19,854,723
EBIT TTM
$-55,917,962
Pretax Income TTM
$-55,919,414
Interest Exp TTM
$1,452
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -58,163,565 | -55,924,814 | 28,313,633 | 8,289,458 | — | -43,062,529 |
| Dec 2024 | 0 | -36,427,435 | -26,567,123 | 72,763,773 | 4,612,049 | — | -25,237,480 |
| Dec 2023 | 0 | -13,671,801 | -37,644,784 | 11,940,411 | 14,072,229 | — | -13,952,178 |
| Dec 2022 | 0 | -12,106,422 | -19,481,602 | 9,111,072 | 12,119,126 | — | -12,744,072 |
TTM Snapshot
Revenues TTM
$-977,799
NetIncome TTM
$-37,800,751
OpCashFlow TTM
$0
Assets (Latest)
$72,763,773
Forward EPS
$-1.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $28.96M | $0.07 | — |
| SER | Serina Therapeutics, Inc. | $28.80M | $1.92 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $29.14M | $3.20 | — |
| GRDX | GridAI Technologies Corp. | $28.58M | $4.61 | — |
| IGC | IGC Pharma, Inc. | $28.55M | $0.29 | — |
News headlines (Yahoo Finance, 1h cache)
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
2026-05-20 11:00 · Yahoo
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-12 17:33 · Yahoo
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-11 20:01 · Yahoo
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
2026-04-07 11:00 · Yahoo
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
2026-04-02 11:00 · Yahoo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
2026-03-18 05:06 · Yahoo
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
2026-03-12 01:04 · Yahoo
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-10 20:01 · Yahoo
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
2026-03-05 12:00 · Yahoo
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
2026-02-17 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.